Phase II IUCRC at Ohio State University: Center for Disruptive Musculoskeletal Innovations (CDMI)

人的生命是以身体运动为特征的。然而，越来越多的成年人因关节疼痛而残疾，这经常限制他们的身体活动。肌肉骨骼疾病（MSD）包括退行性、炎症性和发育性疾病、损伤和过度使用。个人影响范围从对健康的破坏性影响到生活质量的微妙下降。MSD影响了超过一半的美国成年人口，以及75%的65岁以上的人。颠覆性肌肉骨骼创新中心（Center for Disruptive Musculoskeletal Innovations，简称CSDs）的使命是解决与日益增长的MSD负担相关的紧迫社会需求。优先研究主题包括：表征MSD因果途径;开发MSD风险评估，诊断和功能恢复工具;临床护理管理预测分析;医疗器械设计和测试;临床结果评估，重点是成本/效益和患者价值。我们的目标是生成与MSD相关的发病率、病理机制、治疗结果和成本的数据，并根据这些数据开发用于MSD预防、诊断和治疗的新技术。总的来说，这些努力将使美国人更健康，使美国经济更强大，更有竞争力。该中心战略性地加入了四个学术网站，这些网站整合了以下方面的专业知识：肌肉骨骼疾病（MSD）因果途径，MSD风险评估工具，生物力学模型和生物工程（俄亥俄州州立大学- OSU）; MSD生物学、诊断学、临床队列、数字健康和临床数据分析（加州大学旧金山分校弗朗西斯科- UCSF）;医疗器械设计、计算建模、经验测试和测试标准（托莱多大学- UT）;以及先进材料、传感器和化学工程（附属网站东北大学- NU）。UCSF网站专注于数字健康技术和解决方案，再生疗法，临床数据分析以及诊断工具的开发，这些工具有助于更好地将患者与治疗相匹配，并更好地量化患者对治疗的反应。UT的研究中心是器械开发、生物材料和外科手术的临床评估。俄勒冈州立大学应用其敏感的风险暴露工具和个人特定的生物力学模型来阐明身体，心理，社会心理和个人风险因素如何影响伤害风险。该研究路线图确定了项目提案征集的高优先级领域。这些包括基础科学、生物材料、临床结果（包括数字健康）、SMART器械、创新器械/手术技术/器械的开发/评估、医疗保健经济学、骨质疏松症、软组织修复、患者评估工具、测试方法开发、MSD临时路径、MSD风险评估，该奖项反映了NSF的法定使命，并通过使用基金会的知识价值和更广泛的影响进行评估，被认为值得支持审查标准。

Human life is characterized by physical movement. Yet, a growing number of adults are disabled by joint pain that regularly limits their physical activity. Musculoskeletal disorders (MSDs) encompass degenerative, inflammatory and developmental conditions, injury, and overuse. The personal impact ranges from devastating effects on health to subtle reductions in quality of life. MSDs affect more than half of the US adult population, and 75% of those over age 65. The mission of the Center for Disruptive Musculoskeletal Innovations (CDMI) is to address pressing societal needs associated with the growing burden of MSDs. Priority CDMI research themes include: characterizing MSD causal pathways; developing tools for MSD risk assessment, diagnosis, and functional recovery; predictive analytics for clinical care management; medical device design and testing; and clinical outcomes assessment with an emphasis on cost/benefit and patient value. Our goal is to generate data on incidence, pathomechanisms, treatment outcomes, and costs associated with MSDs, and based on these data, develop new technologies for MSD prevention, diagnosis, and treatment. Collectively, these efforts will result in healthier Americans and a stronger and more-competitive U.S. economy.The CDMI has strategically joined four academic sites that integrate expertise in: Musculoskeletal disorder (MSD) causal pathways, tools for MSD risk assessments, biomechanical models, and bioengineering (The Ohio State University - OSU); MSD biology, diagnostics, clinical cohorts, digital health, and clinical data analytics (University of California, San Francisco - UCSF); Medical device design, computational modeling, empirical testing, and testing standards (University of Toledo - UT); and Advanced materials, sensors, and chemical engineering (affiliate site Northeastern University - NU). The UCSF site focuses on digital health technologies and solutions, regenerative therapies, clinical data analytics, and development of diagnostic tools that help better match patients to treatments and better quantify patient response to therapy. UT research centers on development of devices, biomaterials, and clinical assessment of surgical procedures. OSU applies its sensitive risk exposure tools and person-specific biomechanical models to clarify how physical, psychological, psychosocial, and personal risk factors influence injury risk. The CDMI Research Roadmap identifies high priority areas for project proposal solicitation. These include basic science, biomaterials, clinical outcomes (including digital health), SMART devices, development/assessment of innovative devices/surgical techniques/instruments, healthcare economics, osteoporosis, soft tissue repair, patient assessment tools, test method development, MSD casual pathways, MSD risk assessments, and injury prevention.This award reflects NSF's statutory mission and has been deemed worthy of support through evaluation using the Foundation's intellectual merit and broader impacts review criteria.